Evidence map›Paper›PMID 33006377›Full record

ArticleInternational journal of cancer2021

The clonal relation of primary upper urinary tract urothelial carcinoma and paired urothelial carcinoma of the bladder.

Thomas van Doeveren, Jose A Nakauma-Gonzalez, Andrew S Mason, Geert J L H van Leenders, Tahlita C M Zuiverloon, Ellen C Zwarthoff, Isabelle C Meijssen, Angelique C van der Made, Antoine G van der Heijden, Kees Hendricksen and 7 more

Open access · hybridAbstract read
In one paragraph

Article in International journal of cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 22 citations in OpenAlex.

  1. Improved Disease-Free Survival With Adjuvant Chemotherapy After Nephroureterectomy for Upper Tract Urothelial Cancer: Final Results of the POUT Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024
    Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Comparison of different prediction tools for the risk of intravesical recurrence after radical nephroureterectomy for upper tract urothelial carcinoma: a propensity-matched analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024
    Article
  10. Article
  11. Article
  12. Therapeutic strategies for asymptomatic upper urinary tract urothelial carcinoma.Wideochirurgia i inne techniki maloinwazyjne = Videosurgery and other miniinvasive techniques · 2023
    Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Clinical Application ofFrontiers in oncology · 2021
    Review
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 3 countries.

Thomas van DoeverenDepartment of Urology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands.ORCID 0000-0002-9697-4293
Jose A Nakauma-GonzalezDepartment of Urology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands.ORCID 0000-0002-7580-106X
Andrew S MasonJack Birch Unit for Molecular Carcinogenesis, Department of Biology, The University of York, York, UK.ORCID 0000-0002-8222-3974
Geert J L H van LeendersDepartment of Pathology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands.ORCID 0000-0003-2176-9102
Tahlita C M ZuiverloonDepartment of Urology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands.ORCID 0000-0003-0991-0812
Ellen C ZwarthoffDepartment of Pathology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands.ORCID 0000-0002-9853-4953
Isabelle C MeijssenDepartment of Pathology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands.
Angelique C van der MadeDepartment of Pathology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands.
Antoine G van der HeijdenDepartment of Urology, Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands.ORCID 0000-0002-8839-8601
Kees HendricksenDepartment of Urology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
Bas W G van RhijnDepartment of Urology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
Charlotte S VoskuilenDepartment of Urology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.ORCID 0000-0002-6507-118X
Job van RietDepartment of Urology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands.ORCID 0000-0001-7767-7923
Winand N M DinjensDepartment of Pathology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands.ORCID 0000-0002-9298-8380
Hendrikus J DubbinkDepartment of Pathology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands.ORCID 0000-0002-2160-5207
Harmen J G van de WerkenDepartment of Urology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands.ORCID 0000-0002-9794-1477
Joost L BoormansDepartment of Urology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands.ORCID 0000-0002-5127-0436
Erasmus MC Cancer Institute · NLThe Netherlands Cancer Institute · NLRadboud University Nijmegen · NLUniversity of York · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The risk of developing urothelial carcinoma of the bladder (UCB) in patients treated by radical nephroureterectomy (RNU) for an upper urinary tract urothelial carcinoma (UTUC) is 22% to 47% in the 2 years after surgery. Subject of debate remains whether UTUC and the subsequent UCB are clonally related or represent separate origins. To investigate the clonal relationship between both entities, we performed targeted DNA sequencing of a panel of 41 genes on matched normal and tumor tissue of 15 primary UTUC patients treated by RNU who later developed 19 UCBs. Based on the detected tumor-specific DNA aberrations, the paired UTUC and UCB(s) of 11 patients (73.3%) showed a clonal relation, whereas in four patients the molecular results did not indicate a clear clonal relationship. Our results support the hypothesis that UCBs following a primary surgically resected UTUC are predominantly clonally derived recurrences and not separate entities.

Indexed as

AgedCarcinoma, Transitional CellClone CellsFemaleGene Expression ProfilingGenomicsHigh-Throughput Nucleotide SequencingHumansKidney NeoplasmsMaleMiddle AgedNephroureterectomyPolymorphism, Single NucleotideUreteral NeoplasmsUrinary Bladder NeoplasmsUrinary Tractbladder carcinomaclonalityupper urinary tract carcinomaurothelial carcinoma

Identifiers

PMID33006377
PMCPMC7821318
OpenAlexW3090256478

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.